ArticleThe American journal of case reports2025
Castration-Resistant Prostate Cancer Presenting as Bulky Lymphadenopathy: A Case without Bone Metastasis.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Prostate cancer (PCa) tends to spread most often to the regional lymph nodes and then to the skeleton. The prevalence of bone metastases is more than 80% in patients with metastatic PCa. Non-regional lymph node (NRLN) metastasis is defined as cancer cells spreading to lymph nodes distant from the primary tumor and often signals a more advanced stage of cancer. We are reporting such a rare case of NRLN without skeletal metastasis in PCa. CASE REPORT We report a rare case of persistently elevated PSA >20 ng/mL after the treatment of localized PCa in the past. A workup by PSA positron emission tomography (PSMA-PET) scan showed the presence of bulky retroperitoneal massive lymphadenopathy, a type of NRLN metastasis, in the absence of bone metastasis. The patient was then treated with abiraterone plus docetaxel, leading to a decrease in PSA levels from 21 ng/mL to 2.42 ng/mL. The PSMA-PET scan also showed significant shrinkage of lymphadenopathy, marking a favorable response. CONCLUSIONS Castration-resistant PCa typically metastasizes to bone, but our case presents a rare occurrence of bulky NRLN metastasis without skeletal involvement. The use of PSMA-PET imaging and genetic testing can help identify this atypical metastatic pattern. Early recognition is crucial, as it enables more accurate diagnosis and prompt treatment decisions and improves outcomes through timely intervention and personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.